Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation

Transplantation Proceedings

Volumn 46, Issue 1, 2014, Pages 241-244

  De Simone, P ^a   Crocetti, L ^a   Pezzati, D ^a   Bargellini, I ^a   Ghinolfi, D ^a   Carrai, P ^a   Leonardi, G ^a   Della Pina, C ^a   Cioni, D ^a   Pollina, L ^a   Campani, D ^a   Bartolozzi, C ^a   Lencioni, R ^a   Filipponi, F ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SORAFENIB; STEROID; TACROLIMUS; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NICOTINAMIDE; PROTEIN KINASE B; RAPAMYCIN; VASCULOTROPIN A;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; ALCOHOL LIVER CIRRHOSIS; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAND FOOT SYNDROME; HEPATITIS B; HEPATITIS C; HOARSENESS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; DRUG COMBINATION; FACTUAL DATABASE; LIVER FAILURE; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PATIENT SAFETY; PATIENT SELECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PATIENT SAFETY; PATIENT SELECTION; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893630786     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.10.035     Document Type: Article

References (10)

1. J. Rubin, N. Ayoub, F. Kaldas, and S. Saab Management of recurrent hepatocellular carcinoma in liver transplant recipients: A systematic review Exp Clin Transplant 10 2012 531 543
2. S. Bhoori, S. Toffanin, C. Sposito, A. Germini, A. Pellegrinelli, A. Lampis, and V. Mazzaferro Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle J Hepatol 52 2010 771 775
3. C. Sposito, L. Mariani, A. Germini, M. Flores Reyes, M. Bongini, and G. Grossi et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study J Hepatol 59 2013 59 66
4. C. Zavaglia, A. Airoldi, A. Mancuso, M. Vangeli, R. Viganò, and G. Cordone et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature Eur J Gastroenterol Hepatol 25 2013 180 186
5. C. Gomez-Martin, J. Bustamante, J.F. Castroagudin, M. Salcedo, E. Garralda, and M. Testillano et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation Liver Transpl 18 2012 45 52
6. C.T. Frenette, M. Boktour, S.G. Burroughs, A. Kaseb, T.A. Aloia, and J. Galati et al. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation Transpl Int 26 2013 734 739
7. N. Jia, I. Liou, J. Halldorson, R. Carithers, J. Perkins, and J. Reyes et al. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation Anticancer Res 33 2013 2797 2800
8. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O′Beirne J, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma [e-pub ahead of print]. J Hepatol http://dx.doi.org/10. 1016/j.jhep.2013.07.012, published online July 15, 2013.
9. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
10. Banff Working Group on Liver Allograft Pathology Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance Liver Transpl 18 2012 1154 1170